Results of the SARAH trial demonstrate that SIRT resulted in median OS of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and inoperable HCC. The trial, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, further demonstrated that the cumulative incidence of radiologic progression in the liver as the first event was significantly lower in the SIRT group compared to the sorafenib group.

This post comes from the RSS feed of EurekaAlert, you can find more here!

Written by admin